Absence of Anti-RBD Antibodies in SARS-CoV-2 Infected or Naive Individuals Prior to Vaccination with CoronaVac Leads to Short Protection of Only Four Months Duration

The COVID-19 pandemic is the biggest public health threat facing the world today. Multiple vaccines have been approved; however, the emergence of viral variants such as the recent Omicron raises the possibility of booster doses to achieve adequate protection. In Brazil, the CoronaVac (Sinovac, Beiji...

Descripción completa

Detalles Bibliográficos
Autores principales: de Oliveira, Camille F., Neto, Walter F. F., da Silva, Carla P., Ribeiro, Ana Claudia S., Martins, Lívia C., de Sousa, Alana W., Freitas, Maria N. O., Chiang, Jannifer O., Silva, Franko A., dos Santos, Eder B., Medeiros, Daniele B. A., Pinheiro, Gleiciane S., Brandão, Gleiciane F., Carvalho, Valéria L., Azevedo, Raimunda S. S., Vasconcelos, Pedro F. C., Costa, Igor B., Costa, Iran B., dos Santos, Mirleide C., Soares, Luana S., Bedran, Rayssa L. S., Ferreira, James L., Amarilla, Alberto A., Modhiran, Naphak, McMillan, Christopher L. D., Freney, Morgan E., Muller, David A., Watterson, Daniel, Casseb, Lívia M. N., Henriques, Daniele F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147084/
https://www.ncbi.nlm.nih.gov/pubmed/35632447
http://dx.doi.org/10.3390/vaccines10050690

Ejemplares similares

Ejemplares similares